Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues

References

• Aguilar F., Hussain P., Cerutti P. Aflatoxin B, induces the transversion of G-T in codon 249 of the p53 tumour suppressor gene in human hepatocytes. Proceedings of the National Academy of Sciences, USA 1993; 90: 8546–8590
   Google Scholar
• Ayalogu E. O., Snelling J., Lewis D. F. V., Talwar S., Clifford M. N., Ioannides C. Selective induction of hepatic CYP1A2 by the oral administration of caffeine to rats. Biochimica et Biophysica Acta 1995; 1272: 89–94
   PubMed Web of Science ®Google Scholar
• Beresford A. P. CYP1A1: friend or foe. Drug Metabolism Reviews 1993; 25: 503–517
   PubMed Web of Science ®Google Scholar
• Berthou F., Dreano Y., Jacqz-Aigrain E., Guillois B., Beaune P. H. Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica 1992; 22: 671–680
   PubMed Web of Science ®Google Scholar
• Boyd G. W., Coombs M. M., Ioannides C., Lewis D. F. V., Snelling J., Tsakalof A. Species variation in the metabolism of 15,16-dihydro-11-methylcyclopenta[a]phenanthren-17-one to its 3,4-dihydrodiol, the proximate carcinogen. Carcinogenesis 1995; 16: 2351–2355
   PubMed Web of Science ®Google Scholar
• Burke M. D., Mayer R. T. Differential effects of phenobarbitone and 3-methylcholanthrene induction in the hepatic microsomal metabolism and cytochrome P-450 binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxy resorufins). Chemico-Biological Interactions 1983; 45: 243–258
   PubMed Web of Science ®Google Scholar
• Chan W. K., Sui Z., Ortiz De Montellano P. R. Determinants of protein modification versus heme alkylation: inactivation of cytochrome P4501A1 by 1-ethynylpyrene and phenyl-acetylene. Chemical Research in Toxicology 1993; 6: 38–45
   PubMed Web of Science ®Google Scholar
• Cheung Y-L., Snelling J., Mohammed N. N. D., Gray T. J. B., Ioannides C. Interaction with the aromatic hydrocarbon receptor, CYP1A induction and mutagenicity of a series of diaminotoluenes: implications for their carcinogenicity. Toxicology and Applied Pharmacology 1996, in press
   PubMedGoogle Scholar
• Coombs M. M., Bhatt T. S. Cyclopenta[a]phenonthrenes. Cambridge University Press, Cambridge 1987
   Google Scholar
• Crofts F., Cosma G. N., Currie D., Taioli E., Toniolo P., Garte S. J. A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis 1993; 14: 1729–1731
   PubMed Web of Science ®Google Scholar
• Degtyarenko K. N., Archakov A. I. Molecular evolution of P450 superfamily and P450-containing mono-oxygenase systems. FEBS Letters 1993; 332: 1–8
   PubMed Web of Science ®Google Scholar
• Delaforge M., Ioannides C., Parke D. V. Inhibition of cytochrome P-448 mixed function oxidase activity following administration of O-hydroxyellipticine to rats. Chemico-Biological Interactions 1980; 32: 101–110
   PubMed Web of Science ®Google Scholar
• Eaton D. L., Gallagher E. P. Mechanisms of aflatoxin carcinogenesis. Annual Review of Pharmacology and Toxicology 1994; 34: 135–172
   PubMed Web of Science ®Google Scholar
• Edwards R. J., Murray B. P., Murray S., Schulz T., Neubert D., Gant T. W., Thorgeirsson S. S., Boobis A. R., Davies D. S. Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis 1994; 15: 829–836
   PubMed Web of Science ®Google Scholar
• Edwards R. J., Murray B. P., Singleton A. M., Murray S., Davies D. S., Boobis A. R. Identification of the epitope of an anti-peptide antibody which binds to CYP1A2 in many species including man. Biochemical Pharmacology 1993; 46: 213–220
   PubMed Web of Science ®Google Scholar
• Fowler S. M., England P. A., Westlake A. C. G., Rouch D. R., Nickerson D. P., Blunt C., Braybrook D., West S., Wong L. -L., Flitsch S. L. Cytochrome P-450cam mono-oxygenase can be redesigned to catalyse to regioselective aromatic hydroxylation of diphenyl-methane. Chemical Communications. 1994; 2761–2762
   Google Scholar
• Fuhr V., Strobl G., Manaut F., Anders E. -M., Sorgel F., Lopez-De-Brinas E., Chu D. T. W., Pernet A. G., Mahr G., Sanz F., Staib A. H. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Molecular Pharmacology 1993; 43: 191–199
   PubMed Web of Science ®Google Scholar
• Fulco A. J. P450bm.3 and other inducible bacterial P450 cytochromes: biochemistry and regulation. Annual Review of Pharmacology and Toxicology 1991; 31: 177–203
   PubMed Web of Science ®Google Scholar
• Furuya H., Shimizu T., Hatano M., Fujii-Kuriyama Y. Mutations at the distal and proximal sites of cytochrome P-450d changed regio-specificity of acetanilide hydroxylations. Biochemical and Biophysical Research Communications 1989a; 160: 669–676
   PubMed Web of Science ®Google Scholar
• Furuya H., Shimizu T., Hirano K., Hatano M., Fujii-Kuriyama Y., Raag R., Poulos T. L. Site-directed mutageneses of rat liver cytochrome P-450d: catalytic activities toward benzphetamine and 7-ethoxycoumarin. Biochemistry 1989b; 28: 6848–6857
   PubMed Web of Science ®Google Scholar
• Gallagher E. P., Wienkers L. C., Stapleton P. L., Kunze K. L., Eaton D. L. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Research 1994; 54: 101–108
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Crespi C. L., Gelboin H. V. cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutation Research 1991; 247: 113–127
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Gelboin H. V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogen and toxins. Drug Metabolism Reviews 1994; 26: 165–183
   PubMed Web of Science ®Google Scholar
• Graham-Lorence S., Sanders D., Peterson J. A. Mutants affecting substrate recognition and substrate binding in P450BM-P. Cytochrome P450: Biochemistry, Biophysics and Molecular Biology, M. C. Lechner. Libbey, London 1994; 471–473
   Google Scholar
• Guengerich F. P. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Research 1988; 48: 2946–2954
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Human cytochrome P-450 enzymes. Life Sciences 1992a; 50: 1471–1478
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Metabolic activation of carcinogens. Pharmacology and Therapeutics 1992b; 54: 17–61
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Cytochrome P450 enzymes. American Scientist 1993; 81: 440–447
   Web of Science ®Google Scholar
• Guengerich F. P. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicology Letters 1994; 70: 133–138
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology 1991; 4: 391–407
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Shimada T., Raney K. D., Yun C. -H., Meyer D. J., Ketterer B., Harris T. M., Groopman J. D., Kadlubar F. F. Elucidation of catalytic specificities of human cytochrome P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology. Environmental Health Perspectives 1992; 98: 75–80
   PubMedGoogle Scholar
• Halpert J. R., He Y. Engineering of cytochrome P450 2B1 specificity. Journal of Biological Chemistry 1993; 268: 4453–4457
   PubMed Web of Science ®Google Scholar
• Halpert J. R., Guengerich F. P., Bend J. R., Correia M. A. Selective inhibitors of cytochrome P450. Toxicology and Applied Pharmacology 1994; 125: 163–175
   PubMed Web of Science ®Google Scholar
• Hankinson O. The aryl hydrocarbon receptor complex. Annual Review of Pharmacology and Toxicology 1995; 35: 307–340
   PubMed Web of Science ®Google Scholar
• Harvey R. G. Polycyclic Aromatic Hydrocarbons: Chemistry and Carcinogenicity. Cambridge University Press, Cambridge 1991; 64
   Google Scholar
• Hayashi S. I., Watanabe J., Nakachi K., Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. Journal of Biochemistry 1991; 110: 407–411
   PubMed Web of Science ®Google Scholar
• Horn E. P., Tucker M. A., Lambert G., Silverman D., Zametkin D., Sinha R., Hartge T., Landi M. T., Caporaso N. E. A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiology, Biomarkers and Prevention 1995; 4: 529–533
   PubMed Web of Science ®Google Scholar
• Ioannides C., Parke D. V. The cytochrome P4501 gene family of microsomal hemoproteins and their role in the metabolic activation of chemicals. Drug Metabolism Reviews 1990; 22: 1–85
   PubMed Web of Science ®Google Scholar
• Ioannides C., Parke D. V. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metabolism Reviews 1993; 25: 485–501
   PubMed Web of Science ®Google Scholar
• Jerina D. M., Michaud D. P., Feldman R. J., Armstrong R. N., Vyas K. P., Thakker D. R., Yagi H., Thomas P. E., Ryan D. E., Levin W. Stereochemical modeling of the catalytic site of cytochrome P-450c. Microsomes, Drug Oxidations and Drug Toxicity, R. Sato, R. Kato. Japan Scientific Societies Press, Tokyo 1982; 195–201
   Google Scholar
• Kadlubar F. F., Hammons G. J. The role of cytochrome P-450 in the metabolism of chemical carcinogens. Mammalian Cytochromes P-450, F. P. Guengerich. CRC Press, Boca Raton 1987; vol. 2: 81–130
   Google Scholar
• Kawajiri K., Fujii-Kuriyama Y. P450 and human cancer. Japanese Journal of Cancer Research 1991; 82: 1325–1335
   PubMedGoogle Scholar
• Kawajiri K., Watanabe J., Hayashi S. -I. Roles in genetic polymorphisms of drug metabolising enzymes in humans. Journal of Basic and Clinical Physiology and Pharmacology 1992; 3: 76–77
   Google Scholar
• Korzekwa K. R., Jones J. P. Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics 1993; 3: 1–18
   PubMedGoogle Scholar
• Koymans L., Donne-Op Den Kelder G. M., Koppele Te J. M., Vermeulen N. P. E. Cytochromes P450: their active-site structure and mechanism of oxidation. Drug Metabolism Reviews 1993; 25: 325–387
   PubMed Web of Science ®Google Scholar
• Kunze K. L., Trager W. F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chemical Research in Toxicology 1993; 6: 649–656
   PubMed Web of Science ®Google Scholar
• Lake B. G., Lewis D. F. V. The CYP4 family. Cytochromes P450: Metabolic and Toxicological Aspects, C. Ioannides. CRC Press, Boca Raton 1996, in press
   Google Scholar
• Lewis D. F. V. Computer modelling of cytochromes P-450 and their substrates: a rational approach to the prediction of carcinogenicity. Frontiers in Biotransformation 1992; 7: 90–136
   Google Scholar
• Lewis D. F. V. Molecular structural studies in the rationalization of xenobiotic metabolism and toxicity. Toxicology and Ecotoxicology News 1994; 1: 108–112
   Google Scholar
• Lewis D. F. V. Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). Xenobiotica 1995a; 25: 333–366
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V. Molecular modelling of mammalian cytochromes P450 with specific substrates and inhibitors. Cytochromes P450 : Metabolic and Toxicological Aspects, C. Ioannides. CRC Press, Boca Raton 1995b, in press
   Google Scholar
• Lewis D. F. V. COMPACT and the importance of frontier orbitals in toxicity. Toxicology Modelling 1995c; 1: 85–97
   Google Scholar
• Lewis D. F. V. The cytochromes P450: ubiquitous enzymes of metabolism. Manufacturing Chemist 1995d; 66: 35–37
   Google Scholar
• Lewis D. F. V. Cytochromes P450 : Structure, Function and Mechanism. Taylor & Francis, London 1996, in press
   Google Scholar
• Lewis D. F. V., Lake B. G. Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity. Xenobiotica 1995; 25: 585–598
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Lake B. G. The CYP4 family. Cytochromes P450 : Metabolic and Toxicological Aspects, C. Ioannides. CRC Press, Boca Raton 1966, in press
   Google Scholar
• Lewis D. F. V., Moereels H. The sequence homologies of cytochromes P450 and active site geometries. Journal of Computer-Aided Molecular Design 1992; 6: 235–252
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Parke D. V. The genotoxicity of benzanthracenes: a quantitative structure-activity study. Mutation Research 1995; 328: 207–214
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Ioannides C., Parke D. V. Molecular dimensions of the substrate binding site of cytochrome P-448. Biochemical Pharmacology 1986; 35: 2179–2185
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Ioannides C., Parke D. V. Structural requirements for substrates of cytochromes P-450 and P-448. Chemico-Biological Interactions 1987; 64: 39–60
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Moereels H., Lake B. G., Ioannides C., Parke D. V. Molecular modelling of enzymes and receptors involved in carcinogenesis: QSARs and COMPACT-3D. Drug Metabolism Reviews 1994a; 26: 261–185
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Ioannides C., Parke D. V. Molecular modelling of cytochrome P4501A1: a putative access channel explains activity differences between structurally related benzo[a]pyrene and benzo[e]pyrene, and 2-acetylaminofluorene and 4-acetylaminofluorene. Toxicology Letters 1994b; 71: 235–243
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Lake B. G., Ioannides C., Parke D. V. Inhibition of rat hepatic aryl hydrocarbon hydroxylase activity by a series of 7-hydroxy coumarins: QSAR studies. Xenobiotica 1994c; 24: 829–838
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Ioannides C., Parke D. V. Computer graphics analysis of the interaction of alkoxy methylenedioxygenzenes with cytochromes P4501. Toxicology Letters 1995a; 76: 39–45
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Lake B. G., Parke D. V. Molecular orbital-generated quantitative structure-activity relationships in a homologous series of alkoxy resorufins. Xenobiotica 1995b; 25: 1355–1369
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Ioannides C., Parke D. V. Molecular modelling of mammalian cytochromes P450 and evaluation of chemical toxicity and metabolism using COMPACT. QSAR and Moleculer Modelling, F. Sanz. Prous, Paris 1995c, in press
   Google Scholar
• Lindberg R. L. P., Negishi M. Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue. Nature 1989; 339: 632–634
   PubMed Web of Science ®Google Scholar
• Loida P. J., Sligar S. G. Engineering cytochrome P-450cam to increase the stereospecificity and coupling of aliphatic hydroxylation. Protein Engineering 1993; 6: 207–212
   PubMedGoogle Scholar
• McManus M. E., Burgess W. M., Veronese M. E., Huggett A., Quattrochi L. C., Tukey R. H. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochrome P-450. Cancer Research 1990; 50: 3367–3376
   PubMed Web of Science ®Google Scholar
• Martucci C. P., Fishman J. P450 enzymes of estrogen metabolism. Pharmacology and Therapeutics 1993; 57: 237–257
   PubMed Web of Science ®Google Scholar
• Modi S., Primrose W. U., Boyle J. M. B., Gibson C. F., Lian L. -Y., Roberts G. C. K. NMR studies of substrate binding to cytochrome P450BM3: comparisons to cytochrome P450cam'. Biochemistry 1995; 34: 8982–8988
   PubMedGoogle Scholar
• Morrison K. G., Oleksiak M. F., Cornell N. W., Sogin M. L., Stegeman J. J. Identification of cytochrome P-450 1A (CYP1A) genes from two teleost fish, toadfish (Opsanus tau) and scup (Stenotomus chrysops), and phylogenetic analysis of CYP1A genes. Biochemical Journal 1995; 308: 97–104
   PubMed Web of Science ®Google Scholar
• Munro I. C., Kennepohl E., Erickson R. E., Portoghese P. S., Wagner B. M., Easterday O. D., Manley C. H. Safety assessment of ingested heterocyclic amines: initial report. Regulatory Toxicology and Pharmacology 1993; 17: S1–S109
   PubMed Web of Science ®Google Scholar
• Nedelcheva V., Gut I. P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 1994; 24: 1151–1175
   PubMed Web of Science ®Google Scholar
• Nelson D. R., Strobel H. W. Evolution of cytochrome P-450 proteins. Molecular Biology and Evolution 1987; 4: 572–593
   PubMed Web of Science ®Google Scholar
• Nelson D. R., Koymans L., Kamataki T., Stegeman J. J., Feyereisen R., Waxman D. J., Waterman M. R., Gotoh O., Coon M. J., Gunsalus I. C., Nebert D. W. CYP450 Superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42
   PubMedGoogle Scholar
• Nelson D. R., Kamataki T., Waxman D. J., Guengerich F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O., Okuda K., Nebert D. W. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA and Cell Biology 1993; 12: 1–51
   PubMed Web of Science ®Google Scholar
• Nerurkar P. V., Park S. S., Thomas P. E., Nims R. W., Lubet R. A. Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse. Biochemical Pharmacology 1993; 46: 933–943
   PubMed Web of Science ®Google Scholar
• Parke D. V., Ioannides C., Iwasaki K., Lewis D. F. V. Microsomal enzymes and toxicity. Microsomes and Drug Oxidations, A. R. Boobis, J. Caldwell, F. De Matteis, C. R. Elcombe. Taylor & Francis, London 1985; 402–413
   Google Scholar
• Paulsen M. D., Filipovic D., Sligar S. G., Ornstein R. L. Controlling the regio-specificity and coupling of cytochrome P450cam: T185F mutant increases coupling and abolishes 3-hydroxynorcamphor product. Protein Science 1993; 2: 357–365
   PubMedGoogle Scholar
• Phillips D. H., Grover P. L. Polycyclic hydrocarbon activation: bay regions and beyond. Drug Metabolism Reviews 1994; 26: 443–467
   PubMed Web of Science ®Google Scholar
• Porter T. D., Coon M. J. Cytochromes P-450: multiplicity of isoforms, substrates and catalytic and regulatory mechanisms. Journal of Biological Chemistry 1991; 266: 13469–13472
   PubMed Web of Science ®Google Scholar
• Ravichandran K. G., Boddupalli S. S., Hasemann C. A., Peterson J. A., Deisenhofer J. Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450s. Science 1993; 261: 731–736
   PubMed Web of Science ®Google Scholar
• Sanz F., Lopez-De-Brinas E., Rodriguez J., Manaut F. Theoretical study on the metabolism of caffeine by cytochrome P-4501A2 and its inhibition. Quantitative Structure-Activity Relationships 1994a; 13: 281–284
   Google Scholar
• Sanz F., Lozano J. J., Lopez-De-Brinas E., De-La-Torre R., Manaut F. Carcinogenic activation of cooked food heterocyclic amines by cytochrome P450 1A2. A theoretical study. Cytochrome P450. 8th International Conference, M. C. Lechner. John Libbey, Paris 1994b; 575–578
   Google Scholar
• Sesardic D., Boobis A. R., Murray B. P., Murray S., Segura J., De La Torre R., Davies D. S. Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. British Journal of Clinical Pharmacology 1990; 29: 651–663
   PubMed Web of Science ®Google Scholar
• Shimada T., Iwasaki M., Martin M. V., Guengerich F. P. Human liver microsomal cytochrome P450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella Tryphimurium TA 1535/pSK1002. Cancer Research 1989; 49: 3218–3228
   PubMed Web of Science ®Google Scholar
• Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Shimizu T., Murakami Y., Hatano M. Glu318 and Thr319 mutants of cytochrome P4501A2 remarkably enhance homolytic O-O cleavage of alkyl hydroperoxides. Journal of Biological Chemistry 1994; 269: 13296–13304
   PubMed Web of Science ®Google Scholar
• Smith D. A., Abel S. M., Hyland R., Jones B. C. Cytochromes P450: selectivity and measurement in vivo. Xenobiotica 1996; 26, in press
   Google Scholar
• Snyderwine E. G., Buonarati M. H., Felton J. S., Turtletaub K. W. Metabolism of the food-derived mutagen/carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in nonhuman primates. Carcinogenesis 1993; 14: 2517–2522
   PubMed Web of Science ®Google Scholar
• Soucek P., Gut I. Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 1992; 22: 83–103
   PubMed Web of Science ®Google Scholar
• Spatzenegger M., Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews 1995; 27: 397–417
   PubMed Web of Science ®Google Scholar
• Tsang W. S., Griffin G. W. Metabolic Activation of Polynuclear Aromatic Hydrocarbons. Pergamon, Oxford 1979; 97
   Google Scholar
• Tuck S. F., Hiroya K., Shimizu T., Hatano M., Ortiz De Montellano P. R. The cytochrome P4501A2 active site: topology and perturbations caused by glutamic acid-318 and threonine-319 mutations. Biochemistry 1993; 32: 2548–2533
   PubMed Web of Science ®Google Scholar
• Tuck S. F., Peterson J. A., Ortiz De Montellano P. R. Active site topologies of bacterial cytochromes P450101 (P450cam), P450108 (P450terp) and P450102 (P450BM-3): in situ rearrangement of their phenyl-iron complexes. Journal of Biological Chemistry 1992; 267: 5614–5620
   PubMedGoogle Scholar
• Wakabayashi K., Nagao M., Esumi H., Sugimura T. Food-derived mutagens and carcinogens. Cancer Research 1992; 52(suppl.)20925–20985
   Google Scholar
• Yang S. K. Stereoselectivity of cytochrome P-450 isozymes and epoxide hydrolase in the metabolism of polycyclic aromatic hydrocarbons. Biochemical Pharmacology 1988; 37: 61–70
   PubMed Web of Science ®Google Scholar
• Yun C. -H., Hammons G. J., Jones G., Martin M. V., Hopkins N. E., Alworth W. L., Guengerich F. P. Modification of cytochrome P4501A2 enzymes by the mechanism-based inactivator 2-ethynylnaphthalene and the photoaffinity label 4-azidobiphenyl. Biochemistry 1992; 31: 10556–10563
   PubMed Web of Science ®Google Scholar
• Zhao K., Murray S., Davies D. S., Boobis A. R., Gooderham N. J. Metabolism of the food derived mutagen and carcinogen 2-amino-1-methyl-6-phenylimidazo (4,5-b) pyridine (PhIP) by human liver microsomes. Carcinogenesis 1994; 15: 1285–1288
   PubMedGoogle Scholar
• Zvelebil M. J. J. M., Wolf C. R., Sternberg M. J. E. A predicted three-dimensional structure of human cytochrome P450: implications for substrate specificity. Protein Engineering 1991; 4: 271–281
   PubMedGoogle Scholar